Abstract:Abstract Background: Cancer cells utilize both oxidative phosphorylation (OXPHOS) and glycolysis to generate energy. Switching between OXPHOS and glycolysis can promote tumor progression. The mechanisms governing oncogenic metabolic reprogramming are largely unknown, but recent data has suggested that Notch1 dysregulation in cancer cells can contribute to altered metabolic phenotypes. We hypothesized that Notch1 signaling supports metabolic reprogramming in pancreatic neuroendocrine tumor (pNET) cells. Methods: We established a Notch1-knockout pNET cell line (BON-N1-KO) by deleting Notch1 at exon 3 in a pNET cell line (BON) using CRISPR/Cas9. Proliferation over time was measured using a trypan blue exclusion test. Seahorse Glycolytic Rate Assay and Mitochondria Stress Test were used to measure the glycolytic and mitochondrial activities of cells. A glycolysis deprivation assay was employed to determine cell viability at varying glucose concentrations. Single end RNAseq was performed using the Illumina NGS platform, to a read depth of 50M. Results: Over time, pNET cells lacking Notch1 (BON-N1-KO) proliferated slower than wildtype (WT) cells (p=0.034). Compared to WT BON, the BON-N1-KO cells had reduced basal oxygen consumption rate (28.2 ± 1.3 vs. 40.7 ± 1.4; p=0.02, ATP production (21.9 ± 1.0 vs. 29.6 ± 0.98; p=0.04), and maximal respiration (39.4 ± 1.7 vs. 63.7 ± 2.1; p=0.004). BON-N1-KO cells also had a reduction in basal glycolysis, as measured by proton efflux rate, compared to WT (48.7 ± 2.6 vs. 57.7 ± 6.2; p=0.2). To further test metabolic reprogramming, WT and BON-N1-KO cells were starved of glucose (0mM), compared to normal glucose (17.5mM) and viability was measured over time. By day 5, the BON-N1-KO group had a viability of 0%, whereas 12.8% of WT cells were alive (p=0.038). To determine if Notch1 loss was associated with altered expression of established metabolic genes, we performed RNAseq. Differential gene expression analysis found that OXPHOS-related genes (UQCC2, COX15, COX20) and glycolysis-related genes (Slc1a1, Slc2a4, Hk1, Hk2) were significantly down-regulated in BON-N1-KO cells. Conclusions: Our study shows that Notch1 signaling facilitates metabolic reprogramming as a survival advantage in pNET cells. Targeting Notch1 signaling to mediate cellular metabolism may be a novel therapeutic strategy in pNETs. Citation Format: Rachael Guenter, Weisheng Chen, Brendon Herring, Yuvasri Golivi, Melissa Sammy, Jason Whitt, Renata Jaskula-Sztul, Herbert Chen, J. Bart Rose. Metabolic reprogramming through Notch1 signaling promotes a survival advantage in pancreatic neuroendocrine tumor cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4463.

Targeting ONECUT3 blocks glycolytic metabolism and potentiates anti-PD-1 therapy in pancreatic cancer

Therapeutic Efficacy of ECs Foxp1 Targeting Hif1α-Hk2 Glycolysis Signal to Restrict Angiogenesis

Therapeutic Efficacy of ECs Foxp1 Targeting Hif1α-Hk2 Α-Hk2 Glycolysis Signal to Restrict Angiogenesis

Deciphering the Genomic and Lncrna Landscapes of Aerobic Glycolysis Identifies Potential Therapeutic Targets in Pancreatic Cancer.

Identification of ONECUT3 as a stemness-related transcription factor regulating NK cell-mediated immune evasion in pancreatic cancer

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies

Targeting Neoadjuvant Chemotherapy-Induced Metabolic Reprogramming in Pancreatic Cancer Promotes Anti-Tumor Immunity and Chemo-Response.

PAF1/HIF1α axis rewires the glycolytic metabolism to fuel aggressiveness of pancreatic cancer

Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect

Knockout of ENO1 leads to metabolism reprogramming and tumor retardation in pancreatic cancer

Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1

High Glucose-Upregulated PD-L1 Expression Through RAS Signaling-Driven Downregulation of PTRH1 Leads to Suppression of T Cell Cytotoxic Function in Tumor Environment

Glycometabolic rearrangements–aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential

Tumor Aerobic Glycolysis Confers Immune Evasion Through Modulating Sensitivity to T Cell-Mediated Bystander Killing Via TNF-α.

Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma

Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming

Abstract 4463: Metabolic reprogramming through Notch1 signaling promotes a survival advantage in pancreatic neuroendocrine tumor cells

Nanodrug Simultaneously Regulates Stromal Extracellular Matrix and Glucose Metabolism for Effective Immunotherapy Against Orthotopic Pancreatic Cancer

Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression

ETS-1: A Potential Target of Glycolysis for Metabolic Therapy by Regulating Glucose Metabolism in Pancreatic Cancer.

Aerobic Glycolysis Promotes Tumor Immune Evasion by Hexokinase2-Mediated Phosphorylation of IκBα.